Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Market Cap	129.58B
Revenue (ttm)	238.56B
Net Income (ttm)	4.64B
Shares Out	23.91M
EPS (ttm)	194.00
PE Ratio	27.94
Forward PE	n/a
Dividend	50.00 (0.93%)
Ex-Dividend Date	Dec 27, 2024

Volume	15,148
Average Volume	17,093
Open	5,390.00
Previous Close	5,390.00
Day's Range	5,380.00 - 5,480.00
52-Week Range	4,900.00 - 7,640.00
Beta	1.27
RSI	46.41
Earnings Date	May 15, 2025

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 214390

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.